Business Context and Reporting Period
This Form 8-K is a current report filed by Silverback Therapeutics, Inc. (not ARS Pharmaceuticals, Inc.) on March 12, 2021. The filing discloses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the appointment of Maria Koehler, M.D., Ph.D. as a Class I director, effective March 12, 2021. Her term expires at the 2021 annual meeting of stockholders. Dr. Koehler has also been appointed to the Nominating Committee.
Compensation and Governance Details
- Equity Grant: Dr. Koehler received an option to purchase 25,000 shares of common stock. This grant replaces the standard initial option grant. The options vest monthly over three years and vest in full upon a change in control.
- Cash Retainer: She will receive an annual cash retainer of $35,000 for Board service.
- Committee Compensation: An additional annual cash retainer of $4,000 is provided for her service on the Nominating Committee.
- Agreements: Dr. Koehler has entered into the Company's standard Indemnification Agreement.
Investor Verification Checklist
- Verify the trading symbol SBTX on The Nasdaq Stock Market LLC.
- Confirm the vesting schedule details for the 25,000 share option grant in the Company's equity incentive plan.
- Review the press release dated March 15, 2021 (Exhibit 99.1) for additional context on the appointment.
- Note that the registrant is an emerging growth company.